Who will benefit from treatment against EGFR?

被引：5

作者：

Arribas, J ^{[1
]}

Baselga, J ^{[1
]}

机构：

[1] Vall Hebron Univ Hosp, Res Inst, Med Oncol Res Program, Barcelona 08035, Spain

来源：

LANCET ONCOLOGY | 2005年 / 6卷 / 05期

关键词：

D O I：

10.1016/S1470-2045(05)70142-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：257 / 258

页数：2

共 8 条

[1] Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry [J].

Chung, KY ;

Shia, J ;

Kemeny, NE ;

Shah, M ;

Schwartz, GK ;

Tse, A ;

Hamilton, A ;

Pan, D ;

Schrag, D ;

Schwartz, L ;

Klimstra, DS ;

Fridman, D ;

Kelsen, DP ;

Saltz, LB .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1803-1810

[2] Epidermal growth factor receptor in non-small-cell lung carcinomas:: Correlation between gene copy number and protein expression and impact on prognosis [J].

Hirsch, FR ;

Varella-Garcia, M ;

Bunn, PA ;

Di Maria, MV ;

Veve, R ;

Bremnes, RM ;

Barón, AE ;

Zeng, C ;

Franklin, WA .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (20) :3798-3807

[3] Drug therapy - Systemic therapy for colorectal cancer [J].

Meyerhardt, JA ;

Mayer, RJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (05) :476-487

[4] Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study [J].

Moroni, M ;

Veronese, S ;

Benvenuti, S ;

Marrapese, G ;

Sartore-Bianchi, A ;

Di Nicolantonio, F ;

Gambacorta, M ;

Siena, S ;

Bardelli, A .

LANCET ONCOLOGY, 2005, 6 (05) :279-286

[5] KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib [J].

Pao, W ;

Wang, TY ;

Riely, GJ ;

Miller, VA ;

Pan, QL ;

Ladanyi, M ;

Zakowski, MF ;

Heelan, RT ;

Kris, MG ;

Varmus, HE .

PLOS MEDICINE, 2005, 2 (01) :57-61

[6] Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions [J].

Pao, W ;

Miller, VA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2556-2568

[7] Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor [J].

Saltz, LB ;

Meropol, NJ ;

Loehrer, PJ ;

Needle, MN ;

Kopit, J ;

Mayer, RJ .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1201-1208

[8] Untangling the ErbB signalling network [J].

Yarden, Y ;

Sliwkowski, MX .

NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2001, 2 (02) :127-137

← 1 →